Medication Monitor



Generic Name (Trade Name—Company)
Notes
March 1, 2018

Dexamethasone intraocular suspension

(Dexycu—Icon Bioscience)
Single-use corticosteroid treats inflammation associated with cataract surgery

FDA has approved dexamethasone intraocular suspension, a dropless, long-acting corticosteroid that treats inflammation associated with cataract surgery.

The biodegradable, extended-release formulation of dexamethasone is administered once via Verisome technology into the posterior chamber of the eye at the end of surgery.

The current standard treatment after cataract surgery is self-administered medicated eye drops several times a day over several weeks.